BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended ...
BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases ...
On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of ...
The Company will host a corporate update conference call on Monday, March 31, 2025 at 4:30 PM ET following its presentation of ... obligations for several business partners. Research and ...
The Company will host a corporate update conference call on Monday, March 31, 2025 at 4:30 PM ET following its presentation of results from ... fulfillment of performance obligations for several ...
More than 300 delegates, sponsors, and Ausure staff gathered at The Star Gold Coast from Feb. 23 to 25 for the Ausure 2025 ...
On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...
2024 and Recent Business Highlights: Achieved key commercial milestone ... and sero-negative autoantibodies for rheumatoid arthritis, in addition to a plenary presentation in collaboration with Johns ...
SAN FRANCISCO--(BUSINESS WIRE)--NerdWallet ... The 2025 NerdWallet Investor Presentation highlights the Company’s recently issued full-year 2026 non-GAAP operating income guidance.
2d
Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated ...
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) a holder of 7.25% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback